Antonio Siccardi

Antonio G. Siccardi (born 1 October 1944, Varese) is an Italian immunologist and virologist.

Antonio Siccardi

MD
Born (1944-10-01) October 1, 1944
Varese
NationalityItalian
Academic background
Alma materUniversity of Pavia
Academic work
DisciplineImmunology
Virology
InstitutionsUniversity of Milan

Siccardi studied at the medical faculty of the University of Pavia and received his M.D. in 1968.[1] He later became associate professor for genetics (1973 to 1980) and then for microbiology (1974 to 1980).[2] After a short research trip to Rome as a full professor (1980 to 1982), he became full Professor for molecular immunology at the University of Milan from 1982 until today.[2] From 1990 to 1994 he was Operative Director of the DIBIT, San Raffaele Scientific Institute in Milan.[2] From 1991 to 1998 he coordinated the HIV/AIDS research at the Ospedale San Raffaele of the University of Milan.[2] He is (2015) professor for molecular immunology at the university of Milan and member of the board of the Istituto Nazionale di Genetica Molecolare (INGM).[3] From 2000 to 2008 he also was a deputy professor for genetics at the Faculty of Psychology of the Università Vita Salute San Raffaele in Milan and from 2006 to today (2015) deputy professor for History of Molecular Genetics at the Faculty of Biotechnology of the Università Vita Salute San Raffaele.[2]

Siccardi's areas of research comprise HIV,[4][5][6] influenza,[7] cancer (especially mesothelioma),[8][9] immunoglobulin E,[10] and vaccine design of recombinant Modified Vaccinia Ankara virus (MVA) or Fowlpoxvirus.[7] Siccardi developed a recombinant MVA-based vector for vaccination with different fluorescent reporter genes, which indicate the progress of genetic recombination with the transgene of an antigen (green, colorless, red).[7][11]

References
  1. biography of Antonio Siccardi Archived 2015-02-17 at the Wayback Machine at the AllergoOncology Symposium 2008.
  2. CV of Antonio Siccardi Archived 2015-02-17 at the Wayback Machine. University of Milan.
  3. Jannis Kounellis per il charity project "all'Arte" (Italian). Men's Vogue Italy, May 22, 2014.
  4. Was zur Hölle sind Chemokine? (German). Interview with Robert Gallo, Der Spiegel no. 50, 1995.
  5. Grassi, F; Meneveri, R; Gullberg, M; Lopalco, L; Rossi, G. B.; Lanza, P; De Santis, C; Brattsand, G; Buttò, S; Ginelli, E (1991). "Human immunodeficiency virus type 1 gp120 mimics a hidden monomorphic epitope borne by class I major histocompatibility complex heavy chains". The Journal of Experimental Medicine. 174 (1): 53–62. doi:10.1084/jem.174.1.53. PMC 2118897. PMID 1711567.
  6. Scarlatti, G; Tresoldi, E; Björndal, A; Fredriksson, R; Colognesi, C; Deng, H. K.; Malnati, M. S.; Plebani, A; Siccardi, A. G.; Littman, D. R.; Fenyö, E. M.; Lusso, P (1997). "In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression". Nature Medicine. 3 (11): 1259–65. doi:10.1038/nm1197-1259. PMID 9359702.
  7. Soprana, E; Panigada, M; Knauf, M; Radaelli, A; Vigevani, L; Palini, A; Villa, C; Malnati, M; Cassina, G; Kurth, R; Norley, S; Siccardi, A. G. (2011). "Joint production of prime/boost pairs of Fowlpox Virus and Modified Vaccinia Ankara recombinants carrying the same transgene". Journal of Virological Methods. 174 (1–2): 22–8. doi:10.1016/j.jviromet.2011.03.013. PMID 21419167.
  8. Guttinger, M; Guidi, F; Chinol, M; Reali, E; Veglia, F; Viale, G; Paganelli, G; Corti, A; Siccardi, A. G. (2000). "Adoptive immunotherapy by avidin-driven cytotoxic T lymphocyte-tumor bridging". Cancer Research. 60 (15): 4211–5. PMID 10945632.
  9. Nigro, E. A.; Brini, A. T.; Soprana, E; Ambrosi, A; Dombrowicz, D; Siccardi, A. G.; Vangelista, L (2009). "Antitumor IgE adjuvanticity: Key role of Fc epsilon RI". The Journal of Immunology. 183 (7): 4530–6. doi:10.4049/jimmunol.0900842. PMID 19748979.
  10. Vangelista, L; Soprana, E; Cesco-Gaspere, M; Mandiola, P; Di Lullo, G; Fucci, R. N.; Codazzi, F; Palini, A; Paganelli, G; Burrone, O. R.; Siccardi, A. G. (2005). "Membrane IgE binds and activates Fc epsilon RI in an antigen-independent manner". Journal of Immunology. 174 (9): 5602–11. doi:10.4049/jimmunol.174.9.5602. PMID 15843559.
  11. Di Lullo, G; Soprana, E; Panigada, M; Palini, A; Erfle, V; Staib, C; Sutter, G; Siccardi, A. G. (2009). "Marker gene swapping facilitates recombinant Modified Vaccinia Virus Ankara production by host-range selection". Journal of Virological Methods. 156 (1–2): 37–43. doi:10.1016/j.jviromet.2008.10.026. PMID 19038289.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.